The use of trastuzumab in adjuvant setting for early stage breast cancer Erken evre meme kanserinin adjuvan tedavisinde trastuzumab

ÖZTOP İ.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, cilt.17, sa.3, ss.184-192, 2007 (Scopus) identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 17 Sayı: 3
  • Basım Tarihi: 2007
  • Dergi Adı: UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
  • Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.184-192
  • Anahtar Kelimeler: Adjuvant treatment, Early breast cancer, Trastuzumab
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Adjuvant treatment with chemotherapy and endocrine therapy reduces markedly rates of recurrence and death due to breast cancer. However, overexpression of HER-2 protein, amplification of the HER-2 gene occur in approximately 15 to 25 percent of breast cancers, and are associated with high risk of recurrence. Trastuzumab, a recombinant monoclonal antibody against HER-2, has been used succesfully in the treatment of metastatic breast cancer that overexpresses HER-2. These results have lead to design trials that testing its role in the adjuvant setting. Recently, four major randomized trials about the adjuvant use of trastuzumab in breast cancer patients have been performed and published. In this review it is aimed to summarize four important adjuvant trastuzumab trials and to discuss its role in the adjuvant treatment.